Principles for a patient-centred transition to low-global warming potential pressurised metered-dose inhalers

David MG Halpin, Alan Kaplan, Debs Field, Maximilian Plank, Tonya Winders, Ashley Woodcock
npj Primary Care Respiratory Medicine · Springer Nature · 2026-10-31 · DOI: 10.1038/s41533-026-00574-7

Аннотация

npj Primary Care Respiratory Medicine, Published online: 31 October 2026; doi:10.1038/s41533-026-00574-7 Pressurised metered-dose inhalers (pMDIs) are a common device type used to deliver various inhaled medicines to the lungs of patients with asthma, chronic obstructive pulmonary disease and other respiratory diseases. Most pMDIs use hydrofluorocarbon (HFC) propellants, such as hydrofluoroalkane (HFA)-134a, which is a powerful greenhouse gas with a 100-year global warming potential (GWP) 1530 times more potent than CO2. Legislation in developed countries, particularly in Europe, will reduce the availability of high-GWP propellants, enforcing the phase-down of HFC-containing pMDIs within the

Читать у издателя →

Похожие статьи